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Introduction
This document is a compilation of the current American
College of Cardiology Foundation/American Heart Asso-
ciation (ACCF/AHA) practice guideline recommendations
for peripheral artery disease from the “ACC/AHA 2005
Guidelines for the Management of Patients With Periph-
eral Arterial Disease (Lower Extremity, Renal, Mesenteric,
and Abdominal Aortic)”* and the “2011 ACCF/AHA
Focused Update of the Guideline for the Management of
Patients With Peripheral Artery Disease (Updating the
2005 Guideline)”.† Updated and new recommendations
rom 2011 are noted and outdated recommendations have
een removed. No new evidence was reviewed, and no
ecommendations included herein are original to this doc-
ment. The ACCF/AHA Task Force on Practice Guide-
ines chooses to republish the recommendations in this
ormat to provide the complete set of practice guideline
ecommendations in a single resource. Because this docu-
ent includes recommendations only, please refer to the
*J Am Coll Cardiol 2006;47:1239-12, http://dx.doi.org/10.1016/j.jacc.2005.10.009
†J Am Coll Cardiol 2011;58:2020-45, http://dx.doi.org/10.1016/j.jacc.2011.08.023espective 2005 and 2011 articles for all introductory and
upportive content until the entire full-text guideline is
evised. In the future, the ACCF/AHA Task Force on
ractice Guidelines will maintain a continuously updated
ull-text guideline.
1. Vascular History and Physical
Examination: Recommendations
CLASS I
1. Individuals at risk for lower extremity peripheral artery disease
(PAD) should undergo a vascular review of symptoms to assess
walking impairment, claudication, ischemic rest pain, and/or the
presence of nonhealing wounds. (Level of Evidence: C)
2. Individuals at risk for lower extremity PAD should undergo
comprehensive pulse examination and inspection of the feet.
(Level of Evidence: C)
3. Individuals over 50 years of age should be asked if they have a
family history of a first-order relative with an abdominal aortic
aneurysm (AAA). (Level of Evidence: C)
2. Lower Extremity PAD: Recommendations
2.1. Clinical Presentation
2.1.1. Asymptomatic
CLASS I
1. A history of walking impairment, claudication, ischemic rest
pain, and/or nonhealing wounds is recommended as a required
component of a standard review of symptoms for adults 50 years
and older who have atherosclerosis risk factors and for adults 70
years and older. (Level of Evidence: C)
. Individuals with asymptomatic lower extremity PAD should be
identified by examination and/or measurement of the ankle-
brachial index (ABI) so that therapeutic interventions known to
diminish their increased risk of myocardial infarction (MI),
stroke, and death may be offered. (Level of Evidence: B)
. Smoking cessation, lipid lowering, and diabetes and hyperten-
sion treatment according to current national treatment guide-
lines are recommended for individuals with asymptomatic lower
extremity PAD. (Level of Evidence: B)
. Antiplatelet therapy is indicated for individuals with asymptom-
atic lower extremity PAD to reduce the risk of adverse cardio-
vascular ischemic events. (Level of Evidence: C)
CLASS IIa
1. An exercise ABI measurement can be useful to diagnose lower
extremity PAD in individuals who are at risk for lower extremity
PAD who have a normal ABI (0.91 to 1.30), are without classic
claudication symptoms, and have no other clinical evidence of
atherosclerosis. (Level of Evidence: C)
2. A toe-brachial index or pulse volume recording measurement can
be useful to diagnose lower extremity PAD in individuals who are
at risk for lower extremity PAD who have an ABI greater than
1.30 and no other clinical evidence of atherosclerosis. (Level of
Evidence: C)
41
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1. Angiotensin-converting enzyme (ACE) inhibition may be consid-
ered for individuals with asymptomatic lower extremity PAD for
cardiovascular risk reduction. (Level of Evidence: C)
2.1.2. Claudication
CLASS I
1. Patients with symptoms of intermittent claudication should un-
dergo a vascular physical examination, including measurement of
the ABI. (Level of Evidence: B)
2. In patients with symptoms of intermittent claudication, the ABI
should be measured after exercise if the resting index is normal.
(Level of Evidence: B)
3. Patients with intermittent claudication should have significant
functional impairment with a reasonable likelihood of symptom-
atic improvement and absence of other disease that would
comparably limit exercise even if the claudication was improved
(e.g., angina, heart failure, chronic respiratory disease, or ortho-
pedic limitations) before undergoing an evaluation for revascu-
larization. (Level of Evidence: C)
. Individuals with intermittent claudication who are offered the
option of endovascular or surgical therapies should: (a) be
provided information regarding supervised claudication exercise
therapy and pharmacotherapy; (b) receive comprehensive risk
factor modification and antiplatelet therapy; (c) have a signifi-
cant disability, either being unable to perform normal work or
having serious impairment of other activities important to the
patient; and (d) have lower extremity PAD lesion anatomy such
that the revascularization procedure would have low risk and a
high probability of initial and long-term success. (Level of Evi-
dence: C)
CLASS III
1. Arterial imaging is not indicated for patients with a normal
postexercise ABI. This does not apply if other atherosclerotic
causes (e.g., entrapment syndromes or isolated internal iliac
artery occlusive disease) are suspected. (Level of Evidence: C)
2.1.3. Critical Limb Ischemia
CLASS I
1. Patients with critical limb ischemia (CLI) should undergo expe-
dited evaluation and treatment of factors that are known to
increase the risk of amputation. (Level of Evidence: C)
2. Patients with CLI in whom open surgical repair is anticipated
should undergo assessment of cardiovascular risk. (Level of
Evidence: B)
3. Patients with a prior history of CLI or who have undergone
successful treatment for CLI should be evaluated at least twice
annually by a vascular specialist owing to the relatively high
incidence of recurrence. (Level of Evidence: C)
4. Patients at risk of CLI (ABI <0.4 in an individual with diabetes,
or any individual with diabetes and known lower extremity PAD)
should undergo regular inspection of the feet to detect objec-
tive signs of CLI. (Level of Evidence: B)
5. The feet should be examined directly, with shoes and socks
removed, at regular intervals after successful treatment of CLI.
(Level of Evidence: C)
6. Patients with CLI and features to suggest atheroembolization
should be evaluated for aneurysmal disease (e.g., abdominal
aortic, popliteal, or common femoral aneurysms). (Level of
Evidence: B)7. Systemic antibiotics should be initiated promptly in patients
with CLI, skin ulcerations, and evidence of limb infection. (Level
of Evidence: B)
8. Patients with CLI and skin breakdown should be referred to
healthcare providers with specialized expertise in wound care.
(Level of Evidence: B)
9. Patients at risk for CLI (those with diabetes, neuropathy,
chronic renal failure, or infection) who develop acute limb
symptoms represent potential vascular emergencies and should
be assessed immediately and treated by a specialist competent
in treating vascular disease. (Level of Evidence: C)
0. Patients at risk for or who have been treated for CLI should
receive verbal and written instructions regarding self-
surveillance for potential recurrence. (Level of Evidence: C)
2.1.4. Acute Limb Ischemia
CLASS I
1. Patients with acute limb ischemia and a salvageable extremity
should undergo an emergent evaluation that defines the ana-
tomic level of occlusion and that leads to prompt endovascular or
surgical revascularization. (Level of Evidence: B)
CLASS III
1. Patients with acute limb ischemia and a nonviable extremity
should not undergo an evaluation to define vascular anatomy or
efforts to attempt revascularization. (Level of Evidence: B)
2.1.5. Prior Limb Arterial Revascularization
CLASS I
1. Long-term patency of infrainguinal bypass grafts should be eval-
uated in a surveillance program, which should include an interval
vascular history, resting ABIs, physical examination, and a
duplex ultrasound at regular intervals if a venous conduit has
been used. (Level of Evidence: B)
CLASS IIa
1. Long-term patency of infrainguinal bypass grafts may be consid-
ered for evaluation in a surveillance program, which may include
conducting exercise ABIs and other arterial imaging studies at
regular intervals. (Level of Evidence: B)
. Long-term patency of endovascular sites may be evaluated in a
surveillance program, which may include conducting exercise
ABIs and other arterial imaging studies at regular intervals.
(Level of Evidence: B)
2.2. Diagnostic Methods
2.2.1. Ankle- and Toe-Brachial Indices,
Segmental Pressure Examination
CLASS I
1. 2011 Updated Recommendation: The resting ABI should be used
to establish the lower extremity PAD diagnosis in patients with
suspected lower extremity PAD, defined as individuals with 1 or
more of the following: exertional leg symptoms, nonhealing
wounds, age 65 and older, or 50 years and older with a history of
smoking or diabetes. (Level of Evidence: B)
. The ABI should be measured in both legs in all new patients with
PAD of any severity to confirm the diagnosis of lower extremity
PAD and establish a baseline. (Level of Evidence: B)
. The toe-brachial index should be used to establish the lower
extremity PAD diagnosis in patients in whom lower extremity
34
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reliable due to noncompressible vessels (usually patients with
long-standing diabetes or advanced age). (Level of Evidence: B)
4. Leg segmental pressure measurements are useful to establish
the lower extremity PAD diagnosis when anatomic localization of
lower extremity PAD is required to create a therapeutic plan.
(Level of Evidence: B)
5. 2011 New Recommendation: ABI results should be uniformly
reported with noncompressible values defined as greater than
1.40, normal values 1.00 to 1.40, borderline 0.91 to 0.99, and
abnormal 0.90 or less. (Level of Evidence: B)
2.2.2. Pulse Volume Recording
CLASS IIa
1. Pulse volume recordings are reasonable to establish the initial
lower extremity PAD diagnosis, assess localization and severity,
and follow the status of lower extremity revascularization proce-
dures. (Level of Evidence: B)
2.2.3. Continuous-Wave Doppler Ultrasound
CLASS I
1. Continuous-wave Doppler ultrasound blood flow measurements
are useful to provide an accurate assessment of lower extremity
PAD location and severity, to follow lower extremity PAD pro-
gression, and to provide quantitative follow-up after revascular-
ization procedures. (Level of Evidence: B)
2.2.4. Treadmill Exercise Testing With and Without
ABI Assessments and 6-Minute Walk Test
CLASS I
1. Exercise treadmill tests are recommended to provide the most
objective evidence of the magnitude of the functional limitation
of claudication and to measure the response to therapy. (Level of
Evidence: B)
2. A standardized exercise protocol (either fixed or graded) with a
motorized treadmill should be used to ensure reproducibility of
measurements of pain-free walking distance and maximal walk-
ing distance. (Level of Evidence: B)
. Exercise treadmill tests with measurement of pre-exercise and
postexercise ABI values are recommended to provide diagnostic
data useful in differentiating arterial claudication from nonarte-
rial claudication (“pseudoclaudication”). (Level of Evidence: B)
. Exercise treadmill tests should be performed in individuals with
claudication who are to undergo exercise training (lower extrem-
ity PAD rehabilitation) so as to determine functional capacity,
assess nonvascular exercise limitations, and demonstrate the
safety of exercise. (Level of Evidence: B)
CLASS IIb
1. A 6-minute walk test may be reasonable to provide an objective
assessment of the functional limitation of claudication and
response to therapy in elderly individuals or others not amenable
to treadmill testing. (Level of Evidence: B)
2.2.5. Duplex Ultrasound
CLASS I
1. Duplex ultrasound of the extremities is useful to diagnose
anatomic location and degree of stenosis of PAD. (Level of
Evidence: A)
2. Duplex ultrasound is recommended for routine surveillance after
femoral-popliteal or femoral-tibial-pedal bypass with a venousconduit. Minimum surveillance intervals are approximately 3, 6,
and 12 months, and then yearly after graft placement. (Level of
Evidence: A)
CLASS IIa
1. Duplex ultrasound of the extremities can be useful to select
patients as candidates for endovascular intervention. (Level of
Evidence: B)
2. Duplex ultrasound can be useful to select patients as candidates
for surgical bypass and to select the sites of surgical anastomo-
sis. (Level of Evidence: B)
CLASS IIb
1. The use of duplex ultrasound is not well established to assess
long-term patency of percutaneous transluminal angioplasty.
(Level of Evidence: B)
2. Duplex ultrasound may be considered for routine surveillance
after femoral-popliteal bypass with a synthetic conduit. (Level of
Evidence: B)
2.2.6. Computed Tomographic Angiography
CLASS IIb
1. Computed tomographic angiography (CTA) of the extremities
may be considered to diagnose anatomic location and presence
of significant stenosis in patients with lower extremity PAD.
(Level of Evidence: B)
2. CTA of the extremities may be considered as a substitute for
magnetic resonance angiography (MRA) for those patients with
contraindications to MRA. (Level of Evidence: B)
2.2.7. Magnetic Resonance Angiography
CLASS I
1. MRA of the extremities is useful to diagnose anatomic location
and degree of stenosis of PAD. (Level of Evidence: A)
. MRA of the extremities should be performed with gadolinium
enhancement. (Level of Evidence: B)
. MRA of the extremities is useful in selecting patients with lower
extremity PAD as candidates for endovascular intervention.
(Level of Evidence: A)
CLASS IIb
1. MRA of the extremities may be considered to select patients
with lower extremity PAD as candidates for surgical bypass
and to select the sites of surgical anastomosis. (Level of
Evidence: B)
2. MRA of the extremities may be considered for postrevasculariza-
tion (endovascular and surgical bypass) surveillance in patients
with lower extremity PAD. (Level of Evidence: B)
2.2.8. Contrast Angiography
CLASS I
1. Contrast angiography provides detailed information about arte-
rial anatomy and is recommended for evaluation of patients with
lower extremity PAD when revascularization is contemplated.
(Level of Evidence: B)
2. A history of contrast reaction should be documented before
the performance of contrast angiography and appropriate
pretreatment administered before contrast is given. (Level of
Evidence: B)
3. Decisions regarding the potential utility of invasive therapeutic
interventions (percutaneous or surgical) in patients with lower
extremity PAD should be made with a complete anatomic
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of the occlusive lesion, as well as arterial inflow and outflow
with angiography or a combination of angiography and noninva-
sive vascular techniques. (Level of Evidence: B)
4. Digital subtraction angiography is recommended for contrast
angiographic studies because this technique allows for en-
hanced imaging capabilities compared with conventional un-
subtracted contrast angiography. (Level of Evidence: A)
5. Before performance of contrast angiography, a full history and
complete vascular examination should be performed to optimize
decisions regarding the access site, as well as to minimize
contrast dose and catheter manipulation. (Level of Evidence: C)
6. Selective or super selective catheter placement during lower
extremity angiography is indicated because this can enhance
imaging, reduce contrast dose, and improve sensitivity and
specificity of the procedure. (Level of Evidence: C)
7. The diagnostic lower extremity arteriogram should image the
iliac, femoral, and tibial bifurcations in profile without vessel
overlap. (Level of Evidence: B)
8. When conducting a diagnostic lower extremity arteriogram in
which the significance of an obstructive lesion is ambiguous,
transstenotic pressure gradients and supplementary angulated
views should be obtained. (Level of Evidence: B)
9. Patients with baseline renal insufficiency should receive
hydration before undergoing contrast angiography. (Level of
Evidence: B)
0. Follow-up clinical evaluation, including a physical examination
and measurement of renal function, is recommended within 2
weeks after contrast angiography to detect the presence of
delayed adverse effects, such as atheroembolism, deterioration
in renal function, or access site injury (e.g., pseudoaneurysm or
arteriovenous fistula). (Level of Evidence: C)
CLASS IIa
1. Noninvasive imaging modalities, including MRA, CTA, and color
flow duplex imaging, may be used in advance of invasive imaging
to develop an individualized diagnostic strategic plan, including
assistance in selection of access sites, identification of signifi-
cant lesions, and determination of the need for invasive evalua-
tion. (Level of Evidence: B)
2. Treatment with n-acetylcysteine in advance of contrast angiog-
raphy is suggested for patients with baseline renal insufficiency
(creatinine >2.0 mg per dL). (Level of Evidence: B)
2.3. Treatment
2.3.1. Cardiovascular Risk Reduction
2.3.1.1. LIPID-LOWERING DRUGS
CLASS I
1. Treatment with a hydroxymethyl glutaryl coenzyme-A reductase
inhibitor (statin) medication is indicated for all patients with PAD
to achieve a target low-density lipoprotein cholesterol level of
less than 100 mg per dL. (Level of Evidence: B)
CLASS IIa
1. Treatment with a hydroxymethyl glutaryl coenzyme-A reductase
inhibitor (statin) medication to achieve a target low-density
lipoprotein cholesterol level of less than 70 mg per dL is
reasonable for patients with lower extremity PAD at very high
risk of ischemic events. (Level of Evidence: B)2. Treatment with a fibric acid derivative can be useful for patients
with PAD and low high-density lipoprotein cholesterol, normal
low-density lipoprotein cholesterol, and elevated triglycerides.
(Level of Evidence: C)
2.3.1.2. ANTIHYPERTENSIVE DRUGS
CLASS I
1. Antihypertensive therapy should be administered to hypertensive
patients with lower extremity PAD to achieve a goal of less than
140 mm Hg systolic over 90 mm Hg diastolic (individuals without
diabetes) or less than 130 mm Hg systolic over 80 mm Hg
diastolic (individuals with diabetes and individuals with chronic
renal disease) to reduce the risk of MI, stroke, congestive heart
failure, and cardiovascular death. (Level of Evidence: A)
2. Beta-adrenergic blocking drugs are effective antihypertensive
agents and are not contraindicated in patients with PAD. (Level
of Evidence: A)
CLASS IIa
1. The use of ACE inhibitors is reasonable for symptomatic patients
with lower extremity PAD to reduce the risk of adverse cardio-
vascular events. (Level of Evidence: B)
CLASS IIb
1. ACE inhibitors may be considered for patients with asymptom-
atic lower extremity PAD to reduce the risk of adverse cardio-
vascular events. (Level of Evidence: C)
2.3.1.3. DIABETES THERAPIES
CLASS I
1. Proper foot care, including use of appropriate footwear, chiropody/
podiatric medicine, daily foot inspection, skin cleansing, and use
of topical moisturizing creams, should be encouraged and skin
lesions and ulcerations should be addressed urgently in all
patients with diabetes and lower extremity PAD. (Level of
Evidence: B)
CLASS IIa
1. Treatment of diabetes in individuals with lower extremity PAD by
administration of glucose control therapies to reduce the hemo-
globin A1C to less than 7% can be effective to reduce microvas-
cular complications and potentially improve cardiovascular out-
comes. (Level of Evidence: C)
2.3.1.4. SMOKING CESSATION
CLASS I
1. 2011 New Recommendation: Patients who are smokers or
former smokers should be asked about status of tobacco use at
every visit. (Level of Evidence: A)
. 2011 New Recommendation: Patients should be assisted with
counseling and developing a plan for quitting that may include
pharmacotherapy and/or referral to a smoking cessation pro-
gram. (Level of Evidence: A)
. 2011 Updated Recommendation: Individuals with lower extrem-
ity PAD who smoke cigarettes or use other forms of tobacco
should be advised by each of their clinicians to stop smoking and
offered behavioral and pharmacological treatment. (Level of
Evidence: C)
. 2011 New Recommendation: In the absence of contraindication
or other compelling clinical indication, 1 or more of the following
pharmacological therapies should be offered: varenicline, bupro-
pion, and nicotine replacement therapy. (Level of Evidence: A)
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CLASS IIb
1. The effectiveness of the therapeutic use of folic acid and B12
vitamin supplements in individuals with lower extremity PAD and
homocysteine levels greater than 14 micromoles per liter is not
well established. (Level of Evidence: C)
2.3.1.6. ANTIPLATELET AND ANTITHROMBOTIC DRUGS
CLASS I
1. 2011 Updated Recommendation: Antiplatelet therapy is indi-
cated to reduce the risk of MI, stroke, and vascular death in
individuals with symptomatic atherosclerotic lower extremity
PAD, including those with intermittent claudication or CLI prior
lower extremity revascularization (endovascular or surgical), or
prior amputation for lower extremity ischemia. (Level of Evi-
dence: A)
2. 2011 Updated Recommendation: Aspirin, typically in daily doses
of 75 to 325 mg, is recommended as safe and effective anti-
platelet therapy to reduce the risk of MI, stroke, or vascular
death in individuals with symptomatic atherosclerotic lower
extremity PAD, including those with intermittent claudication or
CLI, prior lower extremity revascularization (endovascular or
surgical), or prior amputation for lower extremity ischemia.
(Level of Evidence: B)
3. 2011 Updated Recommendation: Clopidogrel (75 mg per day) is
recommended as a safe and effective alternative antiplatelet
therapy to aspirin to reduce the risk of MI, ischemic stroke, or
vascular death in individuals with symptomatic atherosclerotic
lower extremity PAD, including those with intermittent claudica-
tion or CLI, prior lower extremity revascularization (endovascular
or surgical), or prior amputation for lower extremity ischemia.
(Level of Evidence: B)
CLASS IIa
1. 2011 New Recommendation: Antiplatelet therapy can be useful
to reduce the risk of MI, stroke, or vascular death in asymptom-
atic individuals with an ABI less than or equal to 0.90. (Level of
Evidence: C)
CLASS IIb
1. 2011 New Recommendation: The usefulness of antiplatelet
therapy to reduce the risk of MI, stroke, or vascular death in
asymptomatic individuals with borderline abnormal ABI, defined
as 0.91 to 0.99, is not well established. (Level of Evidence: A)
2. 2011 New Recommendation: The combination of aspirin and
clopidogrel may be considered to reduce the risk of cardiovas-
cular events in patients with symptomatic atherosclerotic lower
extremity PAD, including those with intermittent claudication or
CLI, prior lower extremity revascularization (endovascular or
surgical), or prior amputation for lower extremity ischemia and
who are not at increased risk of bleeding and who are high
perceived cardiovascular risk. (Level of Evidence: B)
CLASS III: NO BENEFIT
1. 2011 Updated Recommendation: In the absence of any other
proven indication for warfarin, its addition to antiplatelet therapy
to reduce the risk of adverse cardiovascular ischemic events in
individuals with atherosclerotic lower extremity PAD is of no
benefit and is potentially harmful due to increased risk of major
bleeding. (Level of Evidence: B)2.3.2. Claudication
2.3.2.1. EXERCISE AND LOWER EXTREMITY PAD REHABILITATION
CLASS I
1. A program of supervised exercise training is recommended as an
initial treatment modality for patients with intermittent claudi-
cation. (Level of Evidence: A)
2. Supervised exercise training should be performed for a minimum
of 30 to 45 minutes, in sessions performed at least 3 times per
week for a minimum of 12 weeks. (Level of Evidence: A)
CLASS IIb
1. The usefulness of unsupervised exercise programs is not well
established as an effective initial treatment modality for patients
with intermittent claudication. (Level of Evidence: B)
2.3.2.2. MEDICAL AND PHARMACOLOGICAL TREATMENT FOR CLAUDICATION
2.3.2.2.1. CILOSTAZOL
CLASS I
1. Cilostazol (100 mg orally 2 times per day) is indicated as an
effective therapy to improve symptoms and increase walking
distance in patients with lower extremity PAD and intermit-
tent claudication (in the absence of heart failure). (Level of
Evidence: A)
. A therapeutic trial of cilostazol should be considered in all
patients with lifestyle-limiting claudication (in the absence of
heart failure). (Level of Evidence: A)
2.3.2.2.2. PENTOXIFYLLINE
CLASS IIb
1. Pentoxifylline (400 mg 3 times per day) may be considered as
second-line alternative therapy to cilostazol to improve walking
distance in patients with intermittent claudication. (Level of
Evidence: A)
2. The clinical effectiveness of pentoxifylline as therapy for claudica-
tion is marginal and not well established. (Level of Evidence: C)
2.3.2.2.3. OTHER PROPOSED MEDICAL THERAPIES
CLASS IIb
1. The effectiveness of L-arginine for patients with intermittent
claudication is not well established. (Level of Evidence: B)
. The effectiveness of propionyl-L-carnitine as a therapy to improve
walking distance in patients with intermittent claudication is not
well established. (Level of Evidence: B)
. The effectiveness of ginkgo biloba to improve walking distance
for patients with intermittent claudication is marginal and not
well established. (Level of Evidence: B)
CLASS III
1. Oral vasodilator prostaglandins such as beraprost and iloprost
are not effective medications to improve walking distance in
patients with intermittent claudication. (Level of Evidence: A)
2. Vitamin E is not recommended as a treatment for patients with
intermittent claudication. (Level of Evidence: C)
3. Chelation (e.g., ethylenediaminetetraacetic acid) is not indi-
cated for treatment of intermittent claudication and may have
harmful adverse effects. (Level of Evidence: A)
2.3.2.3. ENDOVASCULAR TREATMENT FOR CLAUDICATION
CLASS I
1. Endovascular procedures are indicated for individuals with avocational or lifestyle-limiting disability due to intermittent clau-
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of symptomatic improvement with endovascular intervention and
(a) there has been an inadequate response to exercise or
pharmacological therapy and/or (b) there is a very favorable
risk-benefit ratio (e.g., focal aortoiliac occlusive disease). (Level
of Evidence: A)
2. Endovascular intervention is recommended as the preferred
revascularization technique for TASC type A iliac and femoropop-
liteal arterial lesions. (Level of Evidence: B)
3. Translesional pressure gradients (with and without vasodilation)
should be obtained to evaluate the significance of angiographic
iliac arterial stenoses of 50% to 75% diameter before interven-
tion. (Level of Evidence: C)
4. Provisional stent placement is indicated for use in the iliac
arteries as salvage therapy for a suboptimal or failed result from
balloon dilation (e.g., persistent translesional gradient, residual
diameter stenosis >50%, or flow-limiting dissection). (Level of
Evidence: B)
5. Stenting is effective as primary therapy for common iliac artery
stenosis and occlusions. (Level of Evidence: B)
. Stenting is effective as primary therapy in external iliac artery
stenoses and occlusions. (Level of Evidence: C)
CLASS IIa
1. Stents (and other adjunctive techniques such as lasers, cutting
balloons, atherectomy devices, and thermal devices) can be
useful in the femoral, popliteal, and tibial arteries as salvage
therapy for a suboptimal or failed result from balloon dilation
(e.g., persistent translesional gradient, residual diameter steno-
sis >50%, or flow-limiting dissection). (Level of Evidence: C)
CLASS IIb
1. The effectiveness of stents, atherectomy, cutting balloons, ther-
mal devices, and lasers for the treatment of femoral-popliteal
arterial lesions (except to salvage a suboptimal result from
balloon dilation) is not well-established. (Level of Evidence: A)
. The effectiveness of uncoated/uncovered stents, atherectomy,
cutting balloons, thermal devices, and lasers for the treatment of
infrapopliteal lesions (except to salvage a suboptimal result from
balloon dilation) is not well established. (Level of Evidence: C)
CLASS III
1. Endovascular intervention is not indicated if there is no signifi-
cant pressure gradient across a stenosis despite flow augmen-
tation with vasodilators. (Level of Evidence: C)
. Primary stent placement is not recommended in the femoral,
popliteal, or tibial arteries. (Level of Evidence: C)
. Endovascular intervention is not indicated as prophylactic ther-
apy in an asymptomatic patient with lower extremity PAD. (Level
of Evidence: C)
2.3.2.4. SURGERY FOR CLAUDICATION
2.3.2.4.1. INDICATIONS
CLASS I
1. Surgical interventions are indicated for individuals with claudica-
tion symptoms who have a significant functional disability that is
vocational or lifestyle limiting, who are unresponsive to exercise
or pharmacotherapy, and who have a reasonable likelihood of
symptomatic improvement. (Level of Evidence: B)
CLASS IIb
1. Because the presence of more aggressive atherosclerotic occlu-sive disease is associated with less durable results in patientsyounger than 50 years of age, the effectiveness of surgical
intervention in this population for intermittent claudication is
unclear. (Level of Evidence: B)
CLASS III
1. Surgical intervention is not indicated to prevent progression to
limb-threatening ischemia in patients with intermittent claudica-
tion. (Level of Evidence: B)
2.3.2.4.2. PREOPERATIVE EVALUATION
CLASS I
1. A preoperative cardiovascular risk evaluation should be under-
taken in those patients with lower extremity PAD in whom a
major vascular surgical intervention is planned. (Level of Evi-
dence: B)
2.3.2.4.3. INFLOW PROCEDURES:
ORTOILIAC OCCLUSIVE DISEASE
CLASS I
1. Aortobifemoral bypass is beneficial for patients with vocational-
or lifestyle-disabling symptoms and hemodynamically significant
aortoiliac disease who are acceptable surgical candidates and
who are unresponsive to or unsuitable for exercise, pharmaco-
therapy, or endovascular repair. (Level of Evidence: B)
2. Iliac endarterectomy and aortoiliac or iliofemoral bypass in the
setting of acceptable aortic inflow should be used for the
surgical treatment of unilateral disease or in conjunction with
femoral-femoral bypass for the treatment of a patient with
bilateral iliac artery occlusive disease if the patient is not a
suitable candidate for aortobifemoral bypass grafting. (Level of
Evidence: B)
CLASS IIb
1. Axillofemoral-femoral bypass may be considered for the surgical
treatment of patients with intermittent claudication in very
limited settings, such as chronic infrarenal aortic occlusion
associated with symptoms of severe claudication in patients
who are not candidates for aortobifemoral bypass. (Level of
Evidence: B)
CLASS III
1. Axillofemoral-femoral bypass should not be used for the surgical
treatment of patients with intermittent claudication except in
very limited settings. (Level of Evidence: B)
2.3.2.4.4. OUTFLOW PROCEDURES: INFRAINGUINAL DISEASE
CLASS I
1. Bypasses to the popliteal artery above the knee should be
constructed with autogenous vein when possible. (Level of
Evidence: A)
2. Bypasses to the popliteal artery below the knee should be
constructed with autogenous vein when possible. (Level of
Evidence: B)
CLASS IIa
1. The use of synthetic grafts to the popliteal artery below the knee
is reasonable only when no autogenous vein from ipsilateral or
contralateral leg or arms is available. (Level of Evidence: A)
CLASS IIb
1. Femoral-tibial artery bypasses constructed with autogenous vein
may be considered for the treatment of claudication in rare
instances for certain patients. (Level of Evidence: B)
PD
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effectiveness of the use of synthetic grafts to the popliteal artery
above the knee is not well established. (Level of Evidence: B)
CLASS III
1. Femoral-tibial artery bypasses with synthetic graft material
should not be used for the treatment of claudication. (Level of
Evidence: C)
2.3.2.4.5. FOLLOW-UP AFTER VASCULAR SURGICAL
ROCEDURES
CLASS I
1. Patients who have undergone placement of aortobifemoral by-
pass grafts should be followed up with periodic evaluations that
record any return or progression of claudication symptoms, the
presence of femoral pulses, and ABIs at rest and after exercise.
(Level of Evidence: C)
2. Patients who have undergone placement of a lower extremity
bypass with autogenous vein should undergo periodic evalua-
tions for at least 2 years that record any claudication symptoms;
a physical examination and pulse examination of the proximal,
graft, and outflow vessels; and duplex imaging of the entire
length of the graft, with measurement of peak systolic velocities
and calculation of velocity ratios across all lesions. (Level of
Evidence: C)
3. Patients who have undergone placement of a synthetic lower
extremity bypass graft should, for at least 2 years after implan-
tation, undergo periodic evaluations that record any return or
progression of claudication symptoms; a pulse examination of
the proximal, graft, and outflow vessels; and assessment of ABIs
at rest and after exercise. (Level of Evidence: C)
2.3.3. CLI and Treatment for Limb Salvage
2.3.3.1. MEDICAL AND PHARMACOLOGICAL TREATMENT FOR CLI
CLASS III
1. Parenteral administration of pentoxifylline is not useful for the
treatment of CLI. (Level of Evidence: B)
2.3.3.1.1. PROSTAGLANDINS
CLASS IIb
1. Parenteral administration of PGE-1 or iloprost for 7 to 28 days
may be considered to reduce ischemic pain and facilitate ulcer
healing in patients with CLI, but its efficacy is likely to be limited
to a small percentage of patients. (Level of Evidence: A)
CLASS III
1. Oral iloprost is not an effective therapy to reduce the risk of
amputation or death in patients with CLI. (Level of Evidence: B)
2.3.3.1.2. ANGIOGENIC GROWTH FACTORS
CLASS IIb
1. The efficacy of angiogenic growth factor therapy for treatment of
CLI is not well established and is best investigated in the context
of a placebo-controlled trial. (Level of Evidence: C)
2.3.3.2. ENDOVASCULAR TREATMENTS FOR CLI
CLASS I
1. For individuals with combined inflow and outflow disease with CLI,
inflow lesions should be addressed first. (Level of Evidence: C)
2. For individuals with combined inflow and outflow disease inwhom symptoms of CLI or infection persist after inflow revascu-larization, an outflow revascularization procedure should be
performed. (Level of Evidence: B)
3. If it is unclear whether hemodynamically significant inflow dis-
ease exists, intra-arterial pressure measurements across su-
prainguinal lesions should be measured before and after the
administration of a vasodilator. (Level of Evidence: C)
CLASS IIa
1. 2011 New Recommendation: For patients with limb-threatening
lower extremity ischemia and an estimated life expectancy of 2
years or less in patients in whom an autogenous vein conduit is
not available, balloon angioplasty is reasonable to perform when
possible as the initial procedure to improve distal blood flow.
(Level of Evidence: B)
2. 2011 New Recommendation: For patients with limb-threatening
ischemia and an estimated life expectancy of more than 2 years,
bypass surgery, when possible and when an autogenous vein
conduit is available, is reasonable to perform as the initial
treatment to improve distal blood flow. (Level of Evidence: B)
2.3.3.3. THROMBOLYSIS FOR ACUTE AND CLI
CLASS I
1. Catheter-based thrombolysis is an effective and beneficial ther-
apy and is indicated for patients with acute limb ischemia
(Rutherford categories I and IIa) of less than 14 days’ duration.
(Level of Evidence: A)
CLASS IIa
1. Mechanical thrombectomy devices can be used as adjunctive
therapy for acute limb ischemia due to peripheral arterial occlu-
sion. (Level of Evidence: B)
CLASS IIb
1. Catheter-based thrombolysis orthrombectomy may be consid-
ered for patients with acute limb ischemia (Rutherford category
IIb) of more than 14 days’ duration. (Level of Evidence: B)
2.3.3.4. SURGERY FOR CLI
CLASS I
1. For individuals with combined inflow and outflow disease with CLI,
inflow lesions should be addressed first. (Level of Evidence: B)
2. For individuals with combined inflow and outflow disease in
whom symptoms of CLI or infection persist after inflow revascu-
larization, an outflow revascularization procedure should be
performed. (Level of Evidence: B)
3. Patients who have significant necrosis of the weight-bearing
portions of the foot (in ambulatory patients), an uncorrectable
flexion contracture, paresis of the extremity, refractory ischemic
rest pain, sepsis, or a very limited life expectancy due to
comorbid conditions should be evaluated for primary amputation
of the leg. (Level of Evidence: C)
CLASS III
1. Surgical and endovascular intervention is not indicated in pa-
tients with severe decrements in limb perfusion (e.g., ABI <0.4)
in the absence of clinical symptoms of CLI. (Level of Evidence: C)
2.3.3.4.1. INFLOW PROCEDURES: AORTOILIAC OCCLUSIVE
ISEASE
CLASS I
1. When surgery is to be undertaken, aortobifemoral bypass isrecommended for patients with symptomatic, hemodynamically
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Evidence: A)
2. Iliac endarterectomy, patch angioplasty, or aortoiliac or iliofem-
oral bypass in the setting of acceptable aortic inflow should be
used for the treatment of unilateral disease or in conjunction
with femoral-femoral bypass for the treatment of a patient with
bilateral iliac artery occlusive disease if the patient is not a
suitable candidate for aortobifemoral bypass grafting. (Level of
Evidence: B)
3. Axillofemoral-femoral bypass is indicated for the treatment of
patients with CLI who have extensive aortoiliac disease and are not
candidates for other types of intervention. (Level of Evidence: B)
2.3.3.4.2. OUTFLOW PROCEDURES: INFRAINGUINAL DISEASE
CLASS I
1. Bypasses to the above-knee popliteal artery should be con-
structed with autogenous saphenous vein when possible. (Level
of Evidence: A)
. Bypasses to the below-knee popliteal artery should be constructed
with autogenous vein when possible. (Level of Evidence: A)
. The most distal artery with continuous flow from above and
without a stenosis greater than 20% should be used as the point
of origin for a distal bypass. (Level of Evidence: B)
. The tibial or pedal artery that is capable of providing continuous
and uncompromised outflow to the foot should be used as the
site of distal anastomosis. (Level of Evidence: B)
. Femoral-tibial artery bypasses should be constructed with autoge-
nous vein, including the ipsilateral greater saphenous vein, or if
unavailable, other sources of vein from the leg or arm. (Level of
Evidence: B)
. Composite sequential femoropopliteal-tibial bypass and bypass
to an isolated popliteal arterial segment that has collateral outflow
to the foot are both acceptable methods of revascularization and
should be considered when no other form of bypass with adequate
autogenous conduit is possible. (Level of Evidence: B)
. If no autogenous vein is available, a prosthetic femoral-tibial
bypass, and possibly an adjunctive procedure, such as arterio-
venous fistula or vein interposition or cuff, should be used when
amputation is imminent. (Level of Evidence: B)
CLASS IIa
1. Prosthetic material can be used effectively for bypasses to the
below-knee popliteal artery when no autogenous vein from ipsi-
lateral or contralateral leg or arms is available. (Level of Evi-
dence: B)
2.3.3.4.3. POSTSURGICAL CARE
CLASS I
1. Unless contraindicated, all patients undergoing revascularization
for CLI should be placed on antiplatelet therapy, and this treatment
should be continued indefinitely. (Level of Evidence: A)
2. Patients who have undergone placement of aortobifemoral by-
pass grafts should be followed up with periodic evaluations that
record any return or progression of ischemic symptoms, the
presence of femoral pulses, and ABIs. (Level of Evidence: B)
. If infection, ischemic ulcers, or gangrenous lesions persist and
the ABI is less than 0.8 after correction of inflow, an outflow
procedure should be performed that bypasses all major distal
stenoses and occlusions. (Level of Evidence: A)
. Patients who have undergone placement of a lower extremity
bypass with autogenous vein should undergo for at least 2 yearsperiodic examinations that record any return or progression of
ischemic symptoms; a physical examination, with concentration
on pulse examination of the proximal, graft, and outflow vessels;
and duplex imaging of the entire length of the graft, with
measurement of peak systolic velocities and calculation of
velocity ratios across all lesions. (Level of Evidence: A)
. Patients who have undergone placement of a synthetic lower
extremity bypass graft should undergo periodic examinations
that record any return of ischemic symptoms; a pulse examina-
tion of the proximal, graft, and outflow vessels; and assessment
of ABIs at rest and after exercise for at least 2 years after
implantation. (Level of Evidence: A)
3. Renal Arterial Disease: Recommendations
3.1. Clinical Clues to the Diagnosis of
Renal Artery Stenosis
CLASS I
1. The performance of diagnostic studies to identify clinically
significant renal artery stenosis (RAS) is indicated in patients
with the onset of hypertension before the age of 30 years. (Level
of Evidence: B)
2. The performance of diagnostic studies to identify clinically
significant RAS is indicated in patients with the onset of severe
hypertension [as defined in The Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure: the JNC-7 report] after the
age of 55 years. (Level of Evidence: B)
3. The performance of diagnostic studies to identify clinically
significant RAS is indicated in patients with the following char-
acteristics: (a) accelerated hypertension (sudden and persistent
worsening of previously controlled hypertension); (b) resistant
hypertension (defined as the failure to achieve goal blood pres-
sure in patients who are adhering to full doses of an appropriate
3-drug regimen that includes a diuretic); or (c) malignant hyperten-
sion (hypertension with coexistent evidence of acute end-organ
damage, i.e., acute renal failure, acutely decompensated conges-
tive heart failure, new visual or neurological disturbance, and/or
advanced [grade III to IV] retinopathy). (Level of Evidence: C)
4. The performance of diagnostic studies to identify clinically signifi-
cant RAS is indicated in patients with new azotemia or worsening
renal function after the administration of an ACE inhibitor or an
angiotensin receptor blocking agent. (Level of Evidence: B)
. The performance of diagnostic studies to identify clinically signifi-
cant RAS is indicated in patients with an unexplained atrophic
kidney or a discrepancy in size between the 2 kidneys of greater than
1.5 cm. (Level of Evidence: B)
. The performance of diagnostic studies to identify clinically signifi-
cant RAS is indicated in patients with sudden, unexplained pulmo-
nary edema (especially in azotemic patients). (Level of Evidence: B)
CLASS IIa
1. The performance of diagnostic studies to identify clinically
significant RAS is reasonable in patients with unexplained renal
failure, including individuals starting renal replacement therapy
(dialysis or renal transplantation). (Level of Evidence: B)
CLASS IIb
1. The performance of arteriography to identify significant RAS maybe reasonable in patients with multivessel coronary artery dis-
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arteriography. (Level of Evidence: B)
2. The performance of diagnostic studies to identify clinically signifi-
cant RAS may be reasonable in patients with unexplained conges-
tive heart failure or refractory angina. (Level of Evidence: C)
3.2. Diagnostic Methods
CLASS I
1. Duplex ultrasonography is recommended as a screening test to
establish the diagnosis of RAS. (Level of Evidence: B)
2. CTA (in individuals with normal renal function) is recommended
as a screening test to establish the diagnosis of RAS. (Level of
Evidence: B)
3. MRA is recommended as a screening test to establish the
diagnosis of RAS. (Level of Evidence: B)
. When the clinical index of suspicion is high and the results of
noninvasive tests are inconclusive, catheter angiography is
recommended as a diagnostic test to establish the diagnosis of
RAS. (Level of Evidence: B)
CLASS III
1. Captopril renal scintigraphy is not recommended as a screening
test to establish the diagnosis of RAS. (Level of Evidence: C)
2. Selective renal vein renin measurements are not recommended
as a useful screening test to establish the diagnosis of RAS.
(Level of Evidence: B)
3. Plasma renin activity is not recommended as a useful screening
test to establish the diagnosis of RAS. (Level of Evidence: B)
4. The captopril test (measurement of plasma renin activity after
captopril administration) is not recommended as a useful screen-
ing test to establish the diagnosis of RAS. (Level of Evidence: B)
3.3. Treatment of Renovascular Disease: RAS
3.3.1. Medical Treatment
CLASS I
1. ACE inhibitors are effective medications for treatment of hyper-
tension associated with unilateral RAS. (Level of Evidence: A)
. Angiotensin receptor blockers are effective medications for
treatment of hypertension associated with unilateral RAS. (Level
of Evidence: B)
. Calcium-channel blockers are effective medications for treat-
ment of hypertension associated with unilateral RAS. (Level of
Evidence: A)
. Beta blockers are effective medications for treatment of hyper-
tension associated with RAS. (Level of Evidence: A)
3.3.2. Indications for Revascularization
3.3.2.1. ASYMPTOMATIC STENOSIS
CLASS IIb
1. Percutaneous revascularization may be considered for treatment
of an asymptomatic bilateral or solitary viable kidney with a
hemodynamically significant RAS. (Level of Evidence: C)
2. The usefulness of percutaneous revascularization of an asymp-
tomatic unilateral hemodynamically significant RAS in a viable
kidney is not well established and is presently clinically un-
proven. (Level of Evidence: C)3.3.2.2. HYPERTENSION
CLASS IIa
1. Percutaneous revascularization is reasonable for patients with
hemodynamically significant RAS and accelerated hypertension,
resistant hypertension, malignant hypertension, hypertension
with an unexplained unilateral small kidney, and hypertension
with intolerance to medication. (Level of Evidence: B)
3.3.2.3. PRESERVATION OF RENAL FUNCTION
CLASS IIa
1. Percutaneous revascularization is reasonable for patients with
RAS and progressive chronic kidney disease with bilateral RAS or
a RAS to a solitary functioning kidney. (Level of Evidence: B)
CLASS IIb
1. Percutaneous revascularization may be considered for patients
with RAS and chronic renal insufficiency with unilateral RAS.
(Level of Evidence: C)
3.3.2.4. IMPACT OF RAS ON CONGESTIVE HEART FAILURE AND
UNSTABLE ANGINA
CLASS I
1. Percutaneous revascularization is indicated for patients with
hemodynamically significant RAS and recurrent, unexplained
congestive heart failure or sudden, unexplained pulmonary
edema. (Level of Evidence: B)
CLASS IIa
1. Percutaneous revascularization is reasonable for patients with
hemodynamically significant RAS and unstable angina. (Level of
Evidence: B)
3.3.3. Endovascular Treatment for RAS
CLASS I
1. Renal stent placement is indicated for ostial atherosclerotic RAS
lesions that meet the clinical criteria for intervention. (Level of
Evidence: B)
2. Balloon angioplasty with bailout stent placement if necessary is
recommended for fibromuscular dysplasia lesions. (Level of Evi-
dence: B)
3.3.4. Surgery for RAS
CLASS I
1. Vascular surgical reconstruction is indicated for patients with
fibromuscular dysplastic RAS with clinical indications for inter-
ventions (same as for percutaneous transluminal angioplasty),
especially those exhibiting complex disease that extends into
the segmental arteries and those having macroaneurysms.
(Level of Evidence: B)
2. Vascular surgical reconstruction is indicated for patients with
atherosclerotic RAS and clinical indications for intervention,
especially those with multiple small renal arteries or early
primary branching of the main renal artery. (Level of Evidence: B)
3. Vascular surgical reconstruction is indicated for patients with
atherosclerotic RAS in combination with pararenal aortic recon-
structions (in treatment of aortic aneurysms or severe aortoiliac
occlusive disease). (Level of Evidence: C)
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Recommendations
4.1. Acute Intestinal Ischemia
4.1.1. Acute Intestinal Ischemia Caused by
Arterial Obstruction
4.1.1.1. DIAGNOSIS
CLASS I
1. Patients with acute abdominal pain out of proportion to physical
findings and who have a history of cardiovascular disease should
be suspected of having acute intestinal ischemia. (Level of
Evidence: B)
2. Patients who develop acute abdominal pain after arterial inter-
ventions in which catheters traverse the visceral aorta or any
proximal arteries or who have arrhythmias (such as atrial fibril-
lation) or recent MI should be suspected of having acute
intestinal ischemia. (Level of Evidence: C)
CLASS III
1. In contrast to chronic intestinal ischemia, duplex sonography of
the abdomen is not an appropriate diagnostic tool for suspected
acute intestinal ischemia. (Level of Evidence: C)
4.1.1.2. SURGICAL TREATMENT
CLASS I
1. Surgical treatment of acute obstructive intestinal ischemia in-
cludes revascularization, resection of necrotic bowel, and, when
appropriate, a “second look” operation 24 to 48 hours after the
revascularization. (Level of Evidence: B)
4.1.1.3. ENDOVASCULAR TREATMENT
CLASS IIb
1. Percutaneous interventions (including transcatheter lytic ther-
apy, balloon angioplasty, and stenting) are appropriate in se-
lected patients with acute intestinal ischemia caused by arterial
obstructions. Patients so treated may still require laparotomy.
(Level of Evidence: C)
4.1.2. Acute Nonocclusive Intestinal Ischemia
4.1.2.1. ETIOLOGY
CLASS I
1. Nonocclusive intestinal ischemia should be suspected in pa-
tients with low flow states or shock, especially cardiogenic
shock, who develop abdominal pain. (Level of Evidence: B)
. Nonocclusive intestinal ischemia should be suspected in pa-
tients receiving vasoconstrictor substances and medications
(e.g., cocaine, ergots, vasopressin, or norepinephrine) who develop
abdominal pain. (Level of Evidence: B)
. Nonocclusive intestinal ischemia should be suspected in pa-
tients who develop abdominal pain after coarctation repair or
after surgical revascularization for intestinal ischemia caused by
arterial obstruction. (Level of Evidence: B)
4.1.2.2. DIAGNOSIS
CLASS I
1. Arteriography is indicated in patients suspected of having non-occlusive intestinal ischemia whose condition does not improverapidly with treatment of their underlying disease. (Level of
Evidence: B)
4.1.2.3. TREATMENT
CLASS I
1. Treatment of the underlying shock state is the most important
initial step in treatment of nonocclusive intestinal ischemia.
(Level of Evidence: C)
2. Laparotomy and resection of nonviable bowel is indicated in
patients with nonocclusive intestinal ischemia who have persis-
tent symptoms despite treatment. (Level of Evidence: B)
CLASS IIa
1. Transcatheter administration of vasodilator medications into
the area of vasospasm is indicated in patients with nonocclu-
sive intestinal ischemia who do not respond to systemic
supportive treatment and in patients with intestinal ischemia
due to cocaine or ergot poisoning. (Level of Evidence: B)
4.2. Chronic Intestinal Ischemia
4.2.1. Diagnosis
CLASS I
1. Chronic intestinal ischemia should be suspected in patients
with abdominal pain and weight loss without other explana-
tion, especially those with cardiovascular disease. (Level of
Evidence: B)
2. Duplex ultrasound, CTA, and gadolinium-enhanced MRA are
useful initial tests for supporting the clinical diagnosis of chronic
intestinal ischemia. (Level of Evidence: B)
. Diagnostic angiography, including lateral aortography, should be
obtained in patients suspected of having chronic intestinal
ischemia for whom noninvasive imaging is unavailable or inde-
terminate. (Level of Evidence: B)
4.2.2. Endovascular Treatment for Chronic
Intestinal Ischemia
CLASS I
1. Percutaneous endovascular treatment of intestinal arterial ste-
nosis is indicated in patients with chronic intestinal ischemia.
(Level of Evidence: B)
4.2.3. Surgical Treatment
CLASS I
1. Surgical treatment of chronic intestinal ischemia is indicated in
patients with chronic intestinal ischemia. (Level of Evidence: B)
CLASS IIb
1. Revascularization of asymptomatic intestinal arterial obstruc-
tions may be considered for patients undergoing aortic/renal
artery surgery for other indications. (Level of Evidence: B)
CLASS III
1. Surgical revascularization is not indicated for patients with
asymptomatic intestinal arterial obstructions, except in patients
undergoing aortic/renal artery surgery for other indications.
(Level of Evidence: B)
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Branch Vessels, and the Lower Extremities:
Recommendations
5.1. Abdominal Aortic and Iliac Aneurysms
5.1.1. Etiology
5.1.1.1. ATHEROSCLEROTIC RISK FACTORS
CLASS I
1. In patients with AAAs, blood pressure and fasting serum lipid
values should be monitored and controlled as recommended for
patients with atherosclerotic disease. (Level of Evidence: C)
2. Patients with aneurysms or a family history of aneurysms should
be advised to stop smoking and be offered smoking cessation
interventions, including behavior modification, nicotine replace-
ment, or bupropion. (Level of Evidence: B)
5.1.2. Natural History
5.1.2.1. AORTIC ANEURYSM RUPTURE
CLASS I
1. Patients with infrarenal or juxtarenal AAAs measuring 5.5 cm or
larger should undergo repair to eliminate the risk of rupture.
(Level of Evidence: B)
2. Patients with infrarenal or juxtarenal AAAs measuring 4.0 to 5.4
cm in diameter should be monitored by ultrasound or computed
tomographic scans every 6 to 12 months to detect expansion.
(Level of Evidence: A)
CLASS IIa
1. Repair can be beneficial in patients with infrarenal or juxtarenal
AAAs 5.0 to 5.4 cm in diameter. (Level of Evidence: B)
2. Repair is probably indicated in patients with suprarenal or type IV
thoracoabdominal aortic aneurysms larger than 5.5 to 6.0 cm.
(Level of Evidence: B)
3. In patients with AAAs smaller than 4.0 cm in diameter, monitor-
ing by ultrasound examination every 2 to 3 years is reasonable.
(Level of Evidence: B)
CLASS III
1. Intervention is not recommended for asymptomatic infrarenal or
juxtarenal AAAs if they measure less than 5.0 cm in diameter in
men or less than 4.5 cm in diameter in women. (Level of
Evidence: A)
5.1.3. Diagnosis
5.1.3.1. SYMPTOMATIC AORTIC OR ILIAC ANEURYSMS
CLASS I
1. In patients with the clinical triad of abdominal and/or back pain,
a pulsatile abdominal mass, and hypotension, immediate surgi-
cal evaluation is indicated. (Level of Evidence: B)
2. In patients with symptomatic aortic aneurysms, repair is indi-
cated regardless of diameter. (Level of Evidence: C)
5.1.3.2. SCREENING HIGH-RISK POPULATIONS
CLASS I
1. Men 60 years of age or older who are either the siblings or
offspring of patients with AAAs should undergo physical exami-
nation and ultrasound screening for detection of aortic aneu-
rysms. (Level of Evidence: B)CLASS IIa
1. Men who are 65 to 75 years of age who have ever smoked should
undergo a physical examination and 1-time ultrasound screening
for detection of AAAs. (Level of Evidence: B)
5.1.4. Observational Management
5.1.4.1. BLOOD PRESSURE CONTROL AND BETA-BLOCKADE
CLASS I
1. Perioperative administration of beta-adrenergic blocking agents,
in the absence of contraindications, is indicated to reduce the
risk of adverse cardiac events and mortality in patients with
coronary artery disease undergoing surgical repair of atheroscle-
rotic aortic aneurysms. (Level of Evidence: A)
CLASS IIb
1. Beta-adrenergic blocking agents may be considered to reduce
the rate of aneurysm expansion in patients with aortic aneu-
rysms. (Level of Evidence: B)
5.1.5. Prevention of Aortic Aneurysm Rupture
5.1.5.1. MANAGEMENT OVERVIEW
CLASS I
1. 2011 Updated Recommendation: Open or endovascular repair of
infrarenal AAAs and/or common iliac aneurysms is indicated in
patients who are good surgical candidates. (Level of Evidence: A)
2. 2011 Updated Recommendation: Periodic long-term surveillance
imaging should be performed to monitor for an endoleak, to docu-
ment shrinkage or stability of the excluded aneurysm sac, and to
determine the need for further intervention in patients who have
undergone endovascular repair of infrarenal aortic and/or iliac aneu-
rysms. (Level of Evidence: A)
CLASS IIa
1. 2011 New Recommendation: Open aneurysm repair is reason-
able to perform in patients who are good surgical candidates but
who cannot comply with the periodic long-term surveillance
required after endovascular repair. (Level of Evidence: C)
CLASS IIb
1. 2011 New Recommendation: Endovascular repair of infrarenal
aortic aneurysms in patients who are at high surgical or anes-
thetic risk as determined by the presence of coexisting severe
cardiac, pulmonary, and/or renal disease is of uncertain effec-
tiveness. (Level of Evidence: B)
5.2. Visceral Artery Aneurysms
CLASS I
1. Open repair or catheter-based intervention is indicated for visceral
aneurysms measuring 2.0 cm in diameter or larger in women of
childbearing age who are not pregnant and in patients of either
gender undergoing liver transplantation. (Level of Evidence: B)
CLASS IIa
1. Open repair or catheter-based intervention is probably indicated
for visceral aneurysms 2.0 cm in diameter or larger in women
beyond childbearing age and in men. (Level of Evidence: B)
5.3. Lower Extremity Aneurysms
5.3.1. Natural History
CLASS I
1. In patients with femoral or popliteal aneurysms, ultrasound (orcomputed tomography or magnetic resonance) imaging is rec-
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rysms and AAA. (Level of Evidence: B)
5.3.2. Management
CLASS I
1. Patients with a palpable popliteal mass should undergo an
ultrasound examination to exclude popliteal aneurysm. (Level of
Evidence: B)
2. Patients with popliteal aneurysms 2.0 cm in diameter or larger
should undergo repair to reduce the risk of thromboembolic
complications and limb loss. (Level of Evidence: B)
3. Patients with anastomotic pseudoaneurysms or symptomatic femoral
artery aneurysms should undergo repair. (Level of Evidence: A)
CLASS IIa
1. Surveillance by annual ultrasound imaging is suggested for
patients with asymptomatic femoral artery true aneurysms
smaller than 3.0 cm in diameter. (Level of Evidence: C)
. In patients with acute ischemia and popliteal artery aneurysms
and absent runoff, catheter-directed thrombolysis or mechanical
thrombectomy (or both) is suggested to restore distal runoff and
resolve emboli. (Level of Evidence: B). In patients with asymptomatic enlargement of the popliteal
arteries twice the normal diameter for age and gender, annual
ultrasound monitoring is reasonable. (Level of Evidence: C)
. In patients with femoral or popliteal artery aneurysms, adminis-
tration of antiplatelet medication may be beneficial. (Level of
Evidence: C)
5.3.2.1. CATHETER-RELATED FEMORAL ARTERY PSEUDOANEURYSMS
CLASS I
1. Patients with suspected femoral pseudoaneurysms should be
evaluated by duplex ultrasonography. (Level of Evidence: B)
2. Initial treatment with ultrasound-guided compression or thrombin
injection is recommended in patients with large and/or symp-
tomatic femoral artery pseudoaneurysms. (Level of Evidence: B)
CLASS IIa
1. Surgical repair is reasonable in patients with femoral artery
pseudoaneurysms 2.0 cm in diameter or larger that persist or
recur after ultrasound-guided compression or thrombin injection.
(Level of Evidence: B)
2. Reevaluation by ultrasound 1 month after the original injury can
be useful in patients with asymptomatic femoral artery pseudoa-
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